Nitenpyram is a rapidly acting neonicotinoid insecticide widely used in veterinary medicine for the immediate elimination of adult fleas in dogs and cats. Owing to its selective mechanism of action and rapid renal excretion, nitenpyram exhibits one of the safest drug interaction profiles among ectoparasiticides. This article evaluates available scientific literature on the pharmacokinetic, pharmacodynamic, and clinical drug interactions of nitenpyram. Findings indicate minimal potential for harmful drug–drug interactions due to its lack of hepatic metabolism, low protein binding, and high specificity for insect nicotinic acetylcholine receptors. However, certain clinical situations—including gastrointestinal irritation, neurological sensitivity, or renal impairment—may influence tolerability when co-administered with other medications. The review highlights the significance of nitenpyram in integrated flea control and underscores the importance of monitoring in special populations.

Nitenpyram, neonicotinoids, drug interactions, pharmacokinetics, veterinary pharmacology, flea control, safety profile.

Tomizawa M, Casida JE. “Neonicotinoid Insecticide Toxicology.” Journal of Agricultural and Food Chemistry, 2005.

Snyder DE, Wiseman S. “Comparative flea kill speed of oral nitenpyram.” Veterinary Parasitology, 2012.

Capstar® (Nitenpyram) Product Monograph, Elanco Animal Health.

Hovda LR, Hooser SB. “Veterinary Toxicology: Insecticides and Acaricides.” Elsevier Veterinary Toxicology, 2018.

Dryden MW. “Control of flea infestations and insecticide resistance.” Veterinary Dermatology, 2019.

ISOX and neonicotinoid safety studies in companion animals. Journal of Veterinary Pharmacology & Therapeutics, various issues.

Plumb DC. Veterinary Drug Handbook, 9th Edition, 2018.